Ranibizumab safe long-term for neovascular age-related macular degeneration

NEW YORK (Reuters Health) – Ranibizumab injections may be safely used for at least three years in
patients with neovascular age-related macular degeneration (nAMD), according to findings from the SECURE
study.
Source: Modern Medicine: Optometry